{"id":19786,"date":"2022-06-29T10:40:39","date_gmt":"2022-06-29T02:40:39","guid":{"rendered":"https:\/\/tbenews.com\/tbe\/?p=19786"},"modified":"2022-10-25T17:24:48","modified_gmt":"2022-10-25T09:24:48","slug":"10-year-booster-interval-of-tbe-vaccine-how-effective-is-it","status":"publish","type":"post","link":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/","title":{"rendered":"10-year booster interval of TBE vaccine: How effective is it?"},"content":{"rendered":"\n
<\/a><\/span><\/div>
\n\n\n\n

Introduction<\/strong><\/p>\n\n\n\n

In Europe, two TBE vaccines are currently licensed, FSME Immun (based on strain Neud\u00f6rfl) and Encepur (based on strain K23). The primary vaccination series for both vaccines consist of three doses given at day 0, 1\u20133 months and 5\u201312 months, with booster doses every 3 to 5 years (dependent on age of the vaccinee, vaccine formulation and country recommendation). When this immunization schedule is followed, a vaccine effectiveness (VE) of about 95% has been measured.<\/p>\n\n\n\n

There are a couple of studies showing that the level of neutralizing antibodies persists for more than five years in most of the vaccinees. In 2006, the Swiss Federal Office of Public Health changed the recommendations for booster intervals and approved a booster interval of 10 years. Now, a retrospective case-control study to evaluate TBE VE in Switzerland has been conducted at <5, 5\u201310 and 10+ years post-vaccination.<\/p>\n\n\n\n

Results<\/strong><\/p>\n\n\n\n

In this retrospective study, the total number of TBE vaccine doses received was determined for cases and controls. Individuals were classified as \u201cunvaccinated\u201d, when they had received no dose (0) of vaccine, \u201cincomplete\u201d after having received 1\u20132 doses, and \u201ccomplete\u201d after 3 or more doses (3+).<\/p>\n\n\n\n

In total, 1828 cases and 3667 controls were matched for this study. Among cases, 8.3% (N=151) had received at least one TBE vaccine dose compared to 45.2% (N=1656) of controls. Of vaccinated cases, 49.7% were \u201cincomplete\u201d and 50.3% were \u201ccomplete\u201d. Of vaccinated controls, 16.8% were \u201cincomplete\u201d and 83.2% were \u201ccomplete\u201d.<\/p>\n\n\n\n

For \u201ccomplete\u201d vaccination, VE was 95.0%, while for \u201cincomplete\u201d vaccination, VE was 76.8%. VE was 91.6%, when the most recent dose was received <5 years. A VE of 95.2% was calculated when the most recent dose was given 5\u201310 years and VE was 98.5% when the last dose was given 10+ years. These numbers were comparable between age groups of 18\u201339, 40\u201359 and 60\u201379 years of age.<\/p>\n\n\n\n

For completely vaccinated cases, median time since last vaccination was 3.8 years compared to 7.8 years for controls. A total of 63.2% of cases had received their last vaccination within the preceding 5 years, 26.3% between 5\u201310 years and 10.5% more than 10 years. For controls, the numbers were 38.0%, 28.8% and 33.3% for <5, 5\u201310 and 10+ years, respectively.<\/p>\n\n\n\n

Discussion<\/strong><\/p>\n\n\n\n

In this study, a VE of 95% has been calculated for completely vaccinated individuals and 69.0% to 82.6% for incomplete vaccination, which was substantially and significantly less for those with a complete vaccination. VE did not decrease in individuals with increasing time after the last vaccine dose. The median time to vaccine failure did not differ between cases having received three doses or having received more than four doses, suggesting no impact of adding an additional vaccine dose.<\/p>\n\n\n\n

In summary, these findings do not indicate a consistent decrease in TBE VE over time among fully vaccinated individuals and support the effectiveness of 10-year TBE booster intervals currently used in Switzerland.<\/p>\n\n\n\n

In this context, it is of interest that the Robert Koch-Institute (Berlin) has recently stated, \u201cthe VE is 97% after basic immunization and according to studies, the protection is still very good 5\u201310 years after basic immunization\u201d (www.rki.de\/impfen-faktenblaetter).<\/p>\n\n\n\n

Literature<\/strong><\/p>\n\n\n\n

Zens et al.
Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020
BMJ Open<\/em>. 2022;12:e061228. doi: 10.1136\/bmjopen-2022-061228.<\/p>\n\n\n\n

Author:<\/strong> Dr. Michael Br\u00f6ker <\/p>\n\n\n\n

Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies.<\/em> <\/p>\n\n\n\n

Compiled<\/strong>: June 2022<\/p>\n<\/span>","protected":false},"excerpt":{"rendered":"

Introduction In Europe, two TBE vaccines are currently licensed, FSME Immun (based on strain Neud\u00f6rfl) and Encepur (based on strain K23). The primary vaccination series for both vaccines consist of three doses given at day 0, 1\u20133 months and 5\u201312 months, with booster doses every 3 to 5 years (dependent on age of the vaccinee, vaccine formulation and country recommendation). When this immunization schedule is followed, a vaccine effectiveness (VE) of about 95% has been measured. There are a couple of studies showing that the level of neutralizing antibodies persists for more than five years in most of the vaccinees. In 2006, the Swiss Federal Office of Public Health changed the recommendations for booster intervals and approved a booster interval of 10 years. Now, a retrospective case-control study to evaluate TBE VE in Switzerland has been conducted at <5, 5\u201310 and 10+ years post-vaccination. Results In this retrospective study, the total number of TBE vaccine doses received was determined for cases and controls. Individuals were classified as \u201cunvaccinated\u201d, when they had received no dose (0) of vaccine, \u201cincomplete\u201d after having received 1\u20132 doses, and \u201ccomplete\u201d after 3 or more doses (3+). In total, 1828 cases and 3667 controls were matched for this study. Among cases, 8.3% (N=151) had received at least one TBE vaccine dose compared to 45.2% (N=1656) of controls. Of vaccinated cases, 49.7% were \u201cincomplete\u201d and 50.3% were \u201ccomplete\u201d. Of vaccinated controls, 16.8% were \u201cincomplete\u201d and 83.2% were \u201ccomplete\u201d. For \u201ccomplete\u201d vaccination, VE was 95.0%, while for \u201cincomplete\u201d vaccination, VE was 76.8%. VE was 91.6%, when the most recent dose was received <5 years. A VE of 95.2% was calculated when the most recent dose was given 5\u201310 years and VE was 98.5% when the last dose was given 10+ years. These numbers were comparable between age groups of 18\u201339, 40\u201359 and 60\u201379 years of age. For completely vaccinated cases, median time since last vaccination was 3.8 years compared to 7.8 years for controls. A total of 63.2% of cases had received their last vaccination within the preceding 5 years, 26.3% between 5\u201310 years and 10.5% more than 10 years. For controls, the numbers were 38.0%, 28.8% and 33.3% for <5, 5\u201310 and 10+ years, respectively. Discussion In this study, a VE of 95% has been calculated for completely vaccinated individuals and 69.0% to 82.6% for incomplete vaccination, which was substantially and significantly less for those with a complete vaccination. VE did not decrease in individuals with increasing time after the last vaccine dose. The median time to vaccine failure did not differ between cases having received three doses or having received more than four doses, suggesting no impact of adding an additional vaccine dose. In summary, these findings do not indicate a consistent decrease in TBE VE over time among fully vaccinated individuals and support the effectiveness of 10-year TBE booster intervals currently used in Switzerland. In this context, it is of interest that the Robert Koch-Institute (Berlin) has recently stated, \u201cthe VE is 97% after basic immunization and according to studies, the protection is still very good 5\u201310 years after basic immunization\u201d (www.rki.de\/impfen-faktenblaetter). Literature Zens et al.Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020BMJ Open. 2022;12:e061228. doi: 10.1136\/bmjopen-2022-061228. Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: June 2022<\/p>\n","protected":false},"author":1354,"featured_media":17156,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[50],"tags":[],"coauthors":[581],"class_list":["post-19786","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news"],"yoast_head":"\n10-year booster interval of TBE vaccine: How effective is it? - TBE Book<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"10-year booster interval of TBE vaccine: How effective is it? - TBE Book\" \/>\n<meta property=\"og:description\" content=\"Introduction In Europe, two TBE vaccines are currently licensed, FSME Immun (based on strain Neud\u00f6rfl) and Encepur (based on strain K23). The primary vaccination series for both vaccines consist of three doses given at day 0, 1\u20133 months and 5\u201312 months, with booster doses every 3 to 5 years (dependent on age of the vaccinee, vaccine formulation and country recommendation). When this immunization schedule is followed, a vaccine effectiveness (VE) of about 95% has been measured. There are a couple of studies showing that the level of neutralizing antibodies persists for more than five years in most of the vaccinees. In 2006, the Swiss Federal Office of Public Health changed the recommendations for booster intervals and approved a booster interval of 10 years. Now, a retrospective case-control study to evaluate TBE VE in Switzerland has been conducted at <5, 5\u201310 and 10+ years post-vaccination. Results In this retrospective study, the total number of TBE vaccine doses received was determined for cases and controls. Individuals were classified as \u201cunvaccinated\u201d, when they had received no dose (0) of vaccine, \u201cincomplete\u201d after having received 1\u20132 doses, and \u201ccomplete\u201d after 3 or more doses (3+). In total, 1828 cases and 3667 controls were matched for this study. Among cases, 8.3% (N=151) had received at least one TBE vaccine dose compared to 45.2% (N=1656) of controls. Of vaccinated cases, 49.7% were \u201cincomplete\u201d and 50.3% were \u201ccomplete\u201d. Of vaccinated controls, 16.8% were \u201cincomplete\u201d and 83.2% were \u201ccomplete\u201d. For \u201ccomplete\u201d vaccination, VE was 95.0%, while for \u201cincomplete\u201d vaccination, VE was 76.8%. VE was 91.6%, when the most recent dose was received <5 years. A VE of 95.2% was calculated when the most recent dose was given 5\u201310 years and VE was 98.5% when the last dose was given 10+ years. These numbers were comparable between age groups of 18\u201339, 40\u201359 and 60\u201379 years of age. For completely vaccinated cases, median time since last vaccination was 3.8 years compared to 7.8 years for controls. A total of 63.2% of cases had received their last vaccination within the preceding 5 years, 26.3% between 5\u201310 years and 10.5% more than 10 years. For controls, the numbers were 38.0%, 28.8% and 33.3% for <5, 5\u201310 and 10+ years, respectively. Discussion In this study, a VE of 95% has been calculated for completely vaccinated individuals and 69.0% to 82.6% for incomplete vaccination, which was substantially and significantly less for those with a complete vaccination. VE did not decrease in individuals with increasing time after the last vaccine dose. The median time to vaccine failure did not differ between cases having received three doses or having received more than four doses, suggesting no impact of adding an additional vaccine dose. In summary, these findings do not indicate a consistent decrease in TBE VE over time among fully vaccinated individuals and support the effectiveness of 10-year TBE booster intervals currently used in Switzerland. In this context, it is of interest that the Robert Koch-Institute (Berlin) has recently stated, \u201cthe VE is 97% after basic immunization and according to studies, the protection is still very good 5\u201310 years after basic immunization\u201d (www.rki.de\/impfen-faktenblaetter). Literature Zens et al.Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020BMJ Open. 2022;12:e061228. doi: 10.1136\/bmjopen-2022-061228. Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: June 2022\" \/>\n<meta property=\"og:url\" content=\"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/\" \/>\n<meta property=\"og:site_name\" content=\"TBE Book\" \/>\n<meta property=\"article:published_time\" content=\"2022-06-29T02:40:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2022-10-25T09:24:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1024\" \/>\n\t<meta property=\"og:image:height\" content=\"217\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Shaqeez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Shaqeez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/\"},\"author\":{\"name\":\"Shaqeez\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\"},\"headline\":\"10-year booster interval of TBE vaccine: How effective is it?\",\"datePublished\":\"2022-06-29T02:40:39+00:00\",\"dateModified\":\"2022-10-25T09:24:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/\"},\"wordCount\":561,\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters2021-1024x217-1.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/\",\"name\":\"10-year booster interval of TBE vaccine: How effective is it? - TBE Book\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters2021-1024x217-1.jpg\",\"datePublished\":\"2022-06-29T02:40:39+00:00\",\"dateModified\":\"2022-10-25T09:24:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#primaryimage\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters2021-1024x217-1.jpg\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2017\\\/11\\\/TBE-Newsletters2021-1024x217-1.jpg\",\"width\":1024,\"height\":217},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"10-year booster interval of TBE vaccine: How effective is it?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#website\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"name\":\"The TBE Book\",\"description\":\"Tick-borne Encephalitis (TBE)\",\"publisher\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#organization\",\"name\":\"Global Health Press\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"contentUrl\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/wp-content\\\/uploads\\\/2019\\\/01\\\/logo-PNG.png\",\"width\":1000,\"height\":715,\"caption\":\"Global Health Press\"},\"image\":{\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/#\\\/schema\\\/person\\\/2bc2ab1f56f93257537a0ce8de903224\",\"name\":\"Shaqeez\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g\",\"caption\":\"Shaqeez\"},\"url\":\"https:\\\/\\\/tbenews.com\\\/tbe\\\/author\\\/shaqeez\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"10-year booster interval of TBE vaccine: How effective is it? - TBE Book","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/","og_locale":"en_US","og_type":"article","og_title":"10-year booster interval of TBE vaccine: How effective is it? - TBE Book","og_description":"Introduction In Europe, two TBE vaccines are currently licensed, FSME Immun (based on strain Neud\u00f6rfl) and Encepur (based on strain K23). The primary vaccination series for both vaccines consist of three doses given at day 0, 1\u20133 months and 5\u201312 months, with booster doses every 3 to 5 years (dependent on age of the vaccinee, vaccine formulation and country recommendation). When this immunization schedule is followed, a vaccine effectiveness (VE) of about 95% has been measured. There are a couple of studies showing that the level of neutralizing antibodies persists for more than five years in most of the vaccinees. In 2006, the Swiss Federal Office of Public Health changed the recommendations for booster intervals and approved a booster interval of 10 years. Now, a retrospective case-control study to evaluate TBE VE in Switzerland has been conducted at <5, 5\u201310 and 10+ years post-vaccination. Results In this retrospective study, the total number of TBE vaccine doses received was determined for cases and controls. Individuals were classified as \u201cunvaccinated\u201d, when they had received no dose (0) of vaccine, \u201cincomplete\u201d after having received 1\u20132 doses, and \u201ccomplete\u201d after 3 or more doses (3+). In total, 1828 cases and 3667 controls were matched for this study. Among cases, 8.3% (N=151) had received at least one TBE vaccine dose compared to 45.2% (N=1656) of controls. Of vaccinated cases, 49.7% were \u201cincomplete\u201d and 50.3% were \u201ccomplete\u201d. Of vaccinated controls, 16.8% were \u201cincomplete\u201d and 83.2% were \u201ccomplete\u201d. For \u201ccomplete\u201d vaccination, VE was 95.0%, while for \u201cincomplete\u201d vaccination, VE was 76.8%. VE was 91.6%, when the most recent dose was received <5 years. A VE of 95.2% was calculated when the most recent dose was given 5\u201310 years and VE was 98.5% when the last dose was given 10+ years. These numbers were comparable between age groups of 18\u201339, 40\u201359 and 60\u201379 years of age. For completely vaccinated cases, median time since last vaccination was 3.8 years compared to 7.8 years for controls. A total of 63.2% of cases had received their last vaccination within the preceding 5 years, 26.3% between 5\u201310 years and 10.5% more than 10 years. For controls, the numbers were 38.0%, 28.8% and 33.3% for <5, 5\u201310 and 10+ years, respectively. Discussion In this study, a VE of 95% has been calculated for completely vaccinated individuals and 69.0% to 82.6% for incomplete vaccination, which was substantially and significantly less for those with a complete vaccination. VE did not decrease in individuals with increasing time after the last vaccine dose. The median time to vaccine failure did not differ between cases having received three doses or having received more than four doses, suggesting no impact of adding an additional vaccine dose. In summary, these findings do not indicate a consistent decrease in TBE VE over time among fully vaccinated individuals and support the effectiveness of 10-year TBE booster intervals currently used in Switzerland. In this context, it is of interest that the Robert Koch-Institute (Berlin) has recently stated, \u201cthe VE is 97% after basic immunization and according to studies, the protection is still very good 5\u201310 years after basic immunization\u201d (www.rki.de\/impfen-faktenblaetter). Literature Zens et al.Retrospective, matched case-control analysis of tickborne encephalitis vaccine effectiveness by booster interval, Switzerland 2006-2020BMJ Open. 2022;12:e061228. doi: 10.1136\/bmjopen-2022-061228. Author: Dr. Michael Br\u00f6ker Michael Br\u00f6ker is a microbiologist\/biochemist by training. He has more than 35 years of experience in the field of biotechnology and vaccinology while working for various pharmaceutical companies. He also worked as curator and expert in committees of foundations, scientific boards and associations as well as for companies. Compiled: June 2022","og_url":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/","og_site_name":"TBE Book","article_published_time":"2022-06-29T02:40:39+00:00","article_modified_time":"2022-10-25T09:24:48+00:00","og_image":[{"width":1024,"height":217,"url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg","type":"image\/jpeg"}],"author":"Shaqeez","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Shaqeez","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#article","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/"},"author":{"name":"Shaqeez","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224"},"headline":"10-year booster interval of TBE vaccine: How effective is it?","datePublished":"2022-06-29T02:40:39+00:00","dateModified":"2022-10-25T09:24:48+00:00","mainEntityOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/"},"wordCount":561,"publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/","url":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/","name":"10-year booster interval of TBE vaccine: How effective is it? - TBE Book","isPartOf":{"@id":"https:\/\/tbenews.com\/tbe\/#website"},"primaryImageOfPage":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#primaryimage"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#primaryimage"},"thumbnailUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg","datePublished":"2022-06-29T02:40:39+00:00","dateModified":"2022-10-25T09:24:48+00:00","breadcrumb":{"@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#primaryimage","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2017\/11\/TBE-Newsletters2021-1024x217-1.jpg","width":1024,"height":217},{"@type":"BreadcrumbList","@id":"https:\/\/tbenews.com\/tbe\/10-year-booster-interval-of-tbe-vaccine-how-effective-is-it\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/tbenews.com\/tbe\/"},{"@type":"ListItem","position":2,"name":"10-year booster interval of TBE vaccine: How effective is it?"}]},{"@type":"WebSite","@id":"https:\/\/tbenews.com\/tbe\/#website","url":"https:\/\/tbenews.com\/tbe\/","name":"The TBE Book","description":"Tick-borne Encephalitis (TBE)","publisher":{"@id":"https:\/\/tbenews.com\/tbe\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/tbenews.com\/tbe\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/tbenews.com\/tbe\/#organization","name":"Global Health Press","url":"https:\/\/tbenews.com\/tbe\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/","url":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","contentUrl":"https:\/\/tbenews.com\/tbe\/wp-content\/uploads\/2019\/01\/logo-PNG.png","width":1000,"height":715,"caption":"Global Health Press"},"image":{"@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/tbenews.com\/tbe\/#\/schema\/person\/2bc2ab1f56f93257537a0ce8de903224","name":"Shaqeez","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g2ce4daa834e38f5ff18a9faa82d1596d","url":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f1c6a04352cef6bb74d75fceabfabb30473aa9958d64ddd93f1feaec90954df3?s=96&d=mm&r=g","caption":"Shaqeez"},"url":"https:\/\/tbenews.com\/tbe\/author\/shaqeez\/"}]}},"_links":{"self":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/19786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/users\/1354"}],"replies":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/comments?post=19786"}],"version-history":[{"count":4,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/19786\/revisions"}],"predecessor-version":[{"id":19914,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/posts\/19786\/revisions\/19914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media\/17156"}],"wp:attachment":[{"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/media?parent=19786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/categories?post=19786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/tags?post=19786"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/tbenews.com\/tbe\/wp-json\/wp\/v2\/coauthors?post=19786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}